P–336 The role of endoplasmic reticulum stress in endometriosis; preliminary results

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
P Yalci. Bahat ◽  
N F Topba. Selçuki ◽  
C Kaya ◽  
I Ozdemir ◽  
E Oral

Abstract Study question Can X-box binding protein 1 (XBP–1) be used in evaluation of endoplasmic reticulum (ER) stress in endometriosis patients? Summary answer High levels of XBP–1 among endometriosis patients indicate an association between ER stress and endometriosis. What is known already ER is responsible for protein folding, lipid synthesis, and calcium homeostasis. ER stress occurs due to the accumulation of unfolded or misfolded proteins in the ER. ER stress causes the activation of several signal transduction cascades, defined as the unfolded protein response (UPR). In the studies conducted with ectopic endometrial tissue and cells, it was reported that UPR plays a role in the pathogenesis of endometriosis. The XBP–1 is a transcription factor involved in UPR, where it regulates ER stress-mediated apoptosis. XBP–1 is also responsible for endometrial cell migration, which is also a part of the pathogenesis of endometriosis. Study design, size, duration This prospective case-controlled study was conducted at University of Health Sciences Turkey, Istanbul Kanuni Sultan Suleyman Training and Research Hospital Department of Obstetrics and Gynecology between March 2020 – August 2020. A total of 60 subjects were included in the study. All patients gave their written informed consent before their enrollment in the study. Participants/materials, setting, methods 30 endometriosis patients aged 18–45 years were included in the study group. Patients with a history of ovarian surgery, endocrine, autoimmune and metabolic disorders, and hormonal treatment during the previous three months were excluded. 30 healthy subjects without endometriosis were included in the control group. Endometriomas were measured with transvaginal ultrasonography and pain was evaluated with visual analogue scale (VAS). XBP–1 levels were determined from serum samples using Human XBP–1 ELISA Kit (Elabscience Co., USA). Main results and the role of chance The mean age of the control group was 28.33±2.49, and the study group was 27.76±2.45 (p = 0.374). The mean endometrioma volume in the study group was calculated to be 9.9± 9.05. The mean XBP–1 level in the control group was 1008.31± 329.05, whereas this level in the study group was significantly higher (2710.65±1484.13, p < 0.001). When the study group was divided according to VAS scores into two groups, the mean XBP–1 level, and endometrioma volumes were significantly higher in the group with VAS scores > 6 (p < 0.001 and p = 0.03 respectively). A receiver operating curve (ROC) analysis was conducted in the study group. The area under the curve AUC for XBP–1 levels was 91% (95%CI: 0.86–0.96, p < 0.001) for the cut-off value of 1279.52 with a sensitivity 87.2%, specificity 86.7%, PPV: 90.4%, NPV: 82.5%, +LR: 6.5, -LR: 0.1. The AUC for VAS scores >6 was 96.2% (95%CI: 0.93–0.98, p < 0.001) for the cut-off value 2227.71, with a sensitivity 90% and a specificity 91.1%, PPV: 87.1%, NPV: 96.1%, +LR: 10, -LR: 0.1. Limitations, reasons for caution A limitation of this study was the methodology of serum sample collection. Since there are no data available on the timing of sample collection with regard to the menstruation cycle of the subjects, samples were collected at the first consultation of the patients without considering the date of their cycle. Wider implications of the findings: In this study, XBP–1 levels in the endometriosis group and also among patients with VAS scores of > 6 were significantly higher. This association between XBP–1 and endometriosis and the positive correlation with pain indicates that XBP–1 can be a potential biomarker, especially in the presence of severe pain symptoms Trial registration number NCT04440397

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
N F Topba. Selcuki ◽  
K Cakmak ◽  
S Yilmaz ◽  
I Ozdemir ◽  
E Oral

Abstract Study question Does endoplasmic reticulum (ER) stress evaluated by X-box binding protein 1 (XBP–1) among patients aged 18–30 years play a role in recurrent pregnancy loss (RPL)? Summary answer High levels of XBP–1 observed in patients with known RPL indicate that ER stress plays an important role in RPL. What is known already Female reproductive tract undergoes dynamic changes during oogenesis which require protein synthesis, folding, maturation, which take place in the ER. ER is also responsible for destruction of unfolded/misfolded proteins. Excess accumulation of these faulty proteins leads to ER stress, which actives unfolded protein response (UPR). XBP–1 is a transcription factor involved in UPR and regulates ER stress-mediated apoptosis. Regulation of ER homeostasis is important in folliculogenesis, oocyte maturation and embryogenesis. It is also known that ER stress has a positive correlation with age and it is associated with age-related diseases. Study design, size, duration This prospective case-controlled study was conducted at University of Health Sciences Turkey, Istanbul Kanuni Sultan Suleyman Training and Research Hospital Department of Obstetrics and Gynecology between March 2020 – September 2020. A total of 70 subjects were included in the study. All patients gave their written informed consent before their enrollment in the study. Participants/materials, setting, methods 38 patients aged 18–30 years with a history of RPL were included in the study. Patients who had miscarriages due to fetal abnormalities, patients with infections, endocrine or genetic disorders, smokers, alcohol and/or drug abusers, with acute/chronic inflammatory diseases, patients using steroids, anti-inflammatory and antioxidant medications were excluded from the study. Age-matched 32 healthy subjects without RPL were included in the control group. XBP–1 levels were determined using Human XBP–1 ELISA Kit (Elabscience Co., USA). Main results and the role of chance The mean age in the control group and in the study group were 25.21±3.3 and 25.26±2.6, respectively and they were statistically similar (p = 0.324). When groups were compared according to thyroid stimulating hormone (TSH) levels and body mass index (BMI), which are additional risk factors of RPL both groups were statistically similar (p = 0.642 and 0.942, respectively). As expected gravidity and abortus numbers were significantly higher in the study group (p < 0.001). A mean XBP–1 level of 1233.41± 3902.97 was determined in the control group. The mean value of the study group was calculated to be 2251.49± 9621.12. Mean XBP–1 level in the study group was significantly high (p < 0.001). A receiver operating curve (ROC) analysis was conducted in the study group. The area under the curve was found to be 87% (95% CI: 79% - 95%). The specificity was 75%, sensitivity was 89%, positive LR was 3.5, negative LR was 0.15, positive predictive value was 80% and negative predictive value was 87% for the cut-off XBP–1 level at 1364.68 pg/mL. Limitations, reasons for caution Small sample size is an important limitation of this study. In addition, evaluating XBP–1 only in serum samples does not let us drive any conclusions on the local changes of ER stress. Studies with larger samples sizes and studying XBP–1 levels in tissue samples of endometrial material is needed. Wider implications of the findings: The significantly high levels of XBP–1 in RPL patients younger than 30 years, indicate higher ER stress in this group even when age dependent increase in ER stress is calculated out of the equation. XBP–1 can be a promising marker in evaluating patients with a fertility wish for RPL risk. Trial registration number NCT04455256


Author(s):  
Niveditha Damodharan ◽  
Roshan Kumar Verma ◽  
Archana Angrup ◽  
Jaimanti Bakshi ◽  
Naresh K Panda

Background and Objectives This study investigates the role of manuka honey in the healing of postoperative mastoid cavity.Subjects and Method This was a single centre prospective study on 40 consecutive patients of chronic otitis media undergoing canal wall down mastoidectomy. Manuka honey soaked in gel foam was kept in the mastoid cavity for the study group and antibiotic soaked gel foam was kept for the control group. Culture swabs from mastoid granulations were sent at various times from both groups. The healing of the mastoid cavity was assessed in the follow up period.Results Preoperatively 15 out of 20 patients (75%) had a positive aural swab culture in the study group while 11 out of 20 (55%) in the control group had a positive aural swab culture. The most common organism isolated was <i>Pseudomonas aeruginosa</i> and <i>Proteus mirabilis</i>. One month after mastoidectomy only 4 patients (20%) had sterile culture and 16 patients (80%) had grown organisms; in the control group, 7 patients (35%) had sterile culture and 13 patients (65%) had growth on culture. The mean merchant scores for the study group and the control were 2.61 (2-5) and 2.05 (1-4), respectively. At 3 months 13 patients (65%) with sterile culture and 7 patients (35%) had growth on culture; in the control group, 16 patients (80%) had sterile culture and 4 had shown persistent growth on culture (<i>p</i>=0.28). All positive cultures were aerobic in both groups. The mean merchant scores for the study group and the control were 1.03 (0-4) and 0.7 (0-3), respectively (<i>p</i>=0.09).Conclusion Healing of mastoid cavity was almost similar in both groups (<i>p</i>>0.05). Manuka honey exhibited antibacterial activity against <i>Pseudomonas</i>, <i>Proteus</i>, <i>Klebsiella</i>, <i>Escherichia coli</i>, <i>Staphylococcus</i>.


2005 ◽  
Vol 28 (2) ◽  
pp. 135-138 ◽  
Author(s):  
A. Monaco ◽  
O. Streni ◽  
M. Marci ◽  
L. Sabetti ◽  
G. Marzo ◽  
...  

Recent studies have confirmed the relationship between head posture, mandibular position and visual focusing. A case-controlled study was conducted to assess the occurrence of ocular convergence defects between subjects with functional mandibular latero-deviation and healthy subjects in pediatric age. Sixty subjects (the study group) presented mandibular latero-deviation classified as functional according to the use of a clinical examination and frontal and basal tele-radiography. Sixty subjects without functional mandibular laterodeviation (control group) were selected randomly from all subjects seeking pediatric dental care and matched by gender and age to study group. All one hundred and twenty subjects were submitted to orthoptic tests performed by the same operator. These results seemed to confirm that in mandibular latero-deviation subjects ocular convergence defects occurred in greater frequency than in controls underlining the importance of role of pediatric dentistry among interdisciplinary cooperation.


2017 ◽  
Vol 11 (5) ◽  
pp. 1580-1587 ◽  
Author(s):  
Xu Feng Peng ◽  
Xiang Guo Lv ◽  
Hong Xie ◽  
Ying Long Sa ◽  
Yue Min Xu ◽  
...  

To evaluate the efficacy and safety of solifenacin in the treatment of bladder spasms after urethroplasty. Patients underwent urethroplasty were randomly assigned to the study group ( n = 165) and the control group ( n = 150). Patients in the study group were treated with solifenacin for 7 days. Patients in the control group were placebo. Each group was further divided into four subgroups: paracentetic suprapubic cystostomy subgroup, traditional suprapubic cystostomy subgroup, former suprapubic cystostomy subgroup, and urethral catheter subgroup. A visual analogue scale (VAS) was used to measure the severity of bladder spasms. The mean duration of spasms, the frequency of spasms, and the incidences of urine extravasation and radiating pain were recorded each day. There were no significant differences in the VAS scores and mean duration of bladder spasms between the study and control groups . However, there was a significantly lower VAS score in the patients taking solifenacin in the paracentetic suprapubic cystostomy subgroup ( p < .05). A similar tendency was noted in the mean duration of bladder spasms in this subgroup. In a comparison of the daily and nightly frequency of spasms within the four subgroups, a significant improvement was noted in the control group within 5 days. A similar difference was not noted within 6 days in the study group. The short-term therapy with solifenacin is an effective and safe method for decreasing the frequency of bladder spasms after urethroplasty. Patients undergoing paracentetic suprapubic cystostomy might be the only subset to benefit from this treatment.


1970 ◽  
Vol 2 (2) ◽  
pp. 20-23
Author(s):  
Samjhana Dhakal ◽  
Shripad Hebbar

Aim: To compare the difference in the cervical length measured digitally or by transabdominal and transvaginal sonogram examination for prediction of preterm labour Method: This was a prospective randomized, controlled study in the Department of Obstetrics and Gynaecology at TMA Pai Hospital, Udupi from March 2001 to May 2002 where 200 women coming for routine antenatal care were recruited for the study. A total of 168 women were evaluated, out of which 145 were control group and 23 cases of threatened preterm labor formed study group. Results: The mean length of cervix measured by TVS at 20- 24wks of pregnancy was 3.87 cm. There after there was a slight decrease in the length mainly towards term and or 36 wks of pregnancy i.e. 3.27 cm. Cervical length measured on an average 0.8 cm more than TVS(4.9CM versus 3.52 cm) Similarly digital examination of cervix yielded shorter length, compared to TVS measurement (2.86 cm versus 3.5 cm). Conclusion: This study has shown TVS is a simple tool for prediction of preterm labour as decrease in cervical length was observed in women with threatened preterm labor (2.34 cm) and this decrease was statistically significant compared to that of the control (3.7 cm). Key words: Trans abdominal, transvaginal, preterm labour      doi:10.3126/njog.v2i2.1450 N. J. Obstet. Gynaecol 2007 Nov-Dec; 2 (2): 20 - 23


Author(s):  
Shweta Sharma ◽  
Ashok Kumar Sharma ◽  
Hans Raj Sharma ◽  
Shivani Sharma

Patients undergoing phacoemulsification with intraocular lens implantation present with dry eye symptoms postoperatively. The present study was done to evaluate the role of carboxymethylcellulose 1% added to conventional therapy to treat ocular discomfort and tear film instability in patients after cataract surgery. METHODS: A prospective, placebo controlled study of 150 patients with age-related cataract after undergoing phacoemulsification with intraocular lens implantation were postoperatively randomized to treatment with conventional therapy plus CMC 1% (study group, n = 75) or to conventional therapy plus 0.9% NaCl (control group, n = 75). Tear film breakup time (TBUT), schirmer test without anesthesia, lissamine green staining and ocular surface disease index (OSDI) scoring were done preoperatively (baseline) and postoperatively at 7 and 30 days.   Results A significant increase in TBUT in the study group as compared to the control group on both day 7 and day 30 was seen (p<0.0001). The OSDI score on day 30 decreased in study group but increased in control group. Schirmer test showed an increase in both the groups on day 7. Day 30 recorded a significant increase in the study group and a decrease in the control group (p<0.0001). Conclusion The present study thus concludes that dry eye can develop immediately after phacoemulsification with a peak on day 7. However, use of 1% carboxymethylcellulose stabilizes the tear film and thus prevents development of dry eye.


2011 ◽  
Vol 2 (1) ◽  
pp. 13-17
Author(s):  
Evgeniya Vladimirovna Akatova ◽  
Olesya Petrovna Nikolin ◽  
Anatoliy Ivanovich Martynov

Summary. Aim. To evaluate the efficiency of placebo-controlled magnerot use on vascular and hemorrhagic manifestations in patients with idiopathic mitral valve prolapse (MVP). Subjects and methods. Seventy-four patients (31,7% males and 68,3% women) with idiopathic MVP were examined during a single-blind placebo-controlled study. They were randomized into 2 groups: 1) magnerot (a study group) and 2) placebo (a control group). The mean age of the study group patients was 30,80,4 years. The placebo group was matched by age (mean age 31,10,2) and gender. There was a female preponderance among the examinees in both groups. The study group patients received MagnerotR tablets containing 500 mg of Mg orotate (32,8 Mg of elementary Mg) in a daily dose of 3000 mg (196,8 mg of elementary Mg) for 6 months. All the patients underwent comprehensive examination before and 6 months after the study. Results. A clinical significant reduction in the degree of vascular disorders was noted in 71,3% of the patients with MVP. The incidence of vascular disorders remained virtually unchanged in the study group. Vascular disorders were significantly alleviated after the therapy. If before the therapy, mild, moderate, and severe vascular disorders were diagnosed in 30,2, 55,9, and 13,9% of cases, respectively; whereas after the therapy these were absent in 16,3% of cases; the patients with mild vascular disorders increased by 2,5-fold and their severe form was undetected. The clinical effect of the therapy on the severity of hemorrhagic syndrome was observed in 81,4% of patients (75% males and 89,5% females) and the therapeutic efficiency that very frequently corresponded to clinical improvement was seen in 2,3%. Conclusion. The effect of magnerot therapy is shown to significantly reduce the incidence and degree of vascular disorders and hemorrhagic syndrome and their clinical picture as a whole.


2021 ◽  
pp. 105566562110128
Author(s):  
Jason R. Stein ◽  
Esperanza Mantilla-Rivas ◽  
Marudeen Aivaz ◽  
Md Sohel Rana ◽  
Ishwarya Shradha Mamidi ◽  
...  

Objective: To analyze safety and efficacy of single-dose ketorolac after primary palatoplasty (PP). Design: Consecutive cohort of patients undergoing PP, comparing to historical controls. Setting: A large academic children’s hospital. Patients, Participants: A consecutive cohort of 111 patients undergoing PP (study n = 47) compared to historical controls (n = 64). Interventions: All patients received intraoperative acetaminophen, dexmedetomidine, and opioids while the study group received an additional single dose of ketorolac (0.5 mg/kg) at the conclusion of PP. Main Outcome Measures: Safety of ketorolac was measured by significant bleeding complications and need for supplementary oxygen. Efficacy was assessed through bleeding, Face Legs Activity Cry Consolability (FLACC) scale, and opioid dose. Results: Length of stay was similar for both groups (control group 38.5 hours [95% CI: 3.6-43.3] versus study group 37.6 hours [95% CI: 31.3-44.0], P = .84). There were no significant differences in all postoperative FLACC scales. The mean dose of opioid rescue medication measured as morphine milligram equivalents did not differ between groups ( P = .56). Significant postoperative hemorrhage was not observed. Conclusions: This is the first prospective study to evaluate the safety and efficacy of single-dose ketorolac after PP. Although lack of standardization between study and historical control groups may have precluded observation of an analgesic benefit, analysis demonstrated a single dose of ketorolac after PP is safe. Further investigations with more patients and different postoperative regimens may clarify the role of ketorolac in improving pain after PP.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 20.2-21
Author(s):  
G. Hatemi ◽  
A. Mahr ◽  
M. Takeno ◽  
D. Kim ◽  
M. Melikoglu ◽  
...  

Background:Oral ulcers (OU) associated with Behçet’s syndrome are often painful, may interfere with the ability to eat and can negatively affect quality of life.1,2Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in the treatment of OU associated with Behçet’s syndrome in a phase III, multicenter, randomized, double-blind, placebo (PBO)-controlled study (RELIEF; BCT-002).3Objectives:To describe the efficacy of APR treatment in improving OU pain associated with Behçet’s syndrome in RELIEF.Methods:Patients were randomized (1:1) to APR 30 mg twice daily (APR 30 BID) or PBO twice daily for a 12-week PBO-controlled phase, followed by a 52-week active treatment extension. Eligible patients were ≥18 years of age and had active Behçet’s syndrome with ≥3 OU at randomization or ≥2 OU at screening and randomization and without active major organ involvement. Clinical improvement in OU was evaluated by the area under the curve for the number of OU through Week 12 (AUCWk0-12; primary efficacy endpoint) and by assessments of OU number. Patient-reported OU pain was evaluated by the 100-mm visual analogue scale (VAS). The statistical tests were 2-sided (α=0.05). The proportions of patients achieving the minimal clinically important difference (MCID) and higher rates of improvement, defined as ≥10-mm,4≥30-mm (3-fold MCID), ≥50-mm (5-fold MCID) improvements in OU pain VAS scores, respectively, were analyzed through Week 12. An ANCOVA model was used to analyze the primary endpoint and assessments of OU number and OU pain (VAS). The proportion of patients achieving improvement in OU pain VAS scores at Week 12 were summarized descriptively.Results:A total of 207 patients were randomized and received ≥1 dose of study medication (APR: n=104; PBO: n=103). At baseline, the mean (SD) number of OU was 4.2 (3.7) in the APR 30 BID group and 3.9 (2.7) in the PBO group, and the mean (SD) OU pain VAS scores were 61.2 (27.6) and 60.8 (26.9), respectively. At Week 12, significantly greater improvements were observed with APR 30 BID vs. PBO in AUCWk0-12(least-squares [LS] mean [SE]: 129.5 [15.9] vs. 222.1 [15.9];P<0.0001), number of OU (LS mean [SE]: 1.1 [0.2] vs. 2.0 [0.3];P=0.0003) and OU pain VAS scores (LS mean [SE] change from baseline: −40.7 [3.3] vs. −15.9 [3.3];P<0.0001). The proportion of patients who achieved the MCID of ≥10-mm improvement in OU pain VAS scores at Week 12 was greater with APR 30 BID vs. PBO; this pattern was also observed for the higher 3- and 5-fold improvements in MCID (Figure 1). Greater proportions of APR 30 BID vs. PBO patients achieved ≥10-mm and ≥30-mm improvements in OU pain VAS scores over 12 weeks. Notably, greater achievement of ≥50-mm improvement in OU pain VAS scores was observed with APR 30 BID vs. PBO as early as Week 1 and maintained up to Week 12 (Figure 2).Conclusion:For patients with active Behçet’s syndrome, APR 30 BID provided significantly greater improvements vs. PBO in OU number and OU pain at Week 12, including the greater proportion of patients achieving MCID and 3- and 5-fold MCID of OU pain in the APR 30 BID group vs. the PBO group. These results indicate a clinically meaningful treatment effect of APR 30 BID on the OU associated with Behçet’s syndrome.References:[1]Kokturk A.Patholog Res Int. 2012;2012:690390.[2]Hatemi G, et al.Ann Rheum Dis. 2008;67:1656-1662.[3]Hatemi G, et al.N Engl J Med. 2019;381:1918-1928. 4. Dworkin RH, et al.J Pain. 2008;9:105-121.Disclosure of Interests:Gulen Hatemi Grant/research support from: BMS, Celgene Corporation, Silk Road Therapeutics – grant/research support, Consultant of: Bayer, Eli Lilly – consultant, Speakers bureau: AbbVie, Mustafa Nevzat, Novartis, UCB – speaker, Alfred Mahr Consultant of: Celgene, Speakers bureau: Roche, Chugai, Mitsuhiro Takeno Speakers bureau: Esai, Tanabe-Mitsubishi – speaker; Celgene Corporation – advisory board, Doyoung Kim: None declared, Melike Melikoglu: None declared, Sue Cheng Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Shannon McCue Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Sven Richter Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Michele Brunori Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Maria Paris Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Mindy Chen Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of the conduct, Yusuf Yazici Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant, Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant


Author(s):  
Nuray Bayar Muluk ◽  
Osman Kürşat Arikan ◽  
Pınar Atasoy ◽  
Rahmi Kiliç ◽  
Eda Tuna Yalçinozan

Abstract Objectives The aim of this study was to investigate the role of CD68 (+) histiocytic macrophages (H-M) in the nasal polyp pathogenesis. Materials and Methods The study group consisted of 24 adult patients with nasal polyposis. The control group consisted of 11 adult patients without nasal polyps. A total of 36 nasal polyp samples (10-nasal cavity, 10-maxillary sinus, and 16-ethmoid sinus) from the study group and 11 inferior turbinate samples from the control group were analyzed by immunohistochemical staining, with monoclonal antibodies against CD68 (+) H-M. Results CD68 positivity was significantly higher than the control group in the subepithelial (SE) layer of the ethmoid sinus, and deep layers of nasal cavity, maxillary, and ethmoid sinuses. In SE and deep layers of ethmoid and maxillary sinuses, CD68 positivity was significantly higher than that of the epithelial layer. In the deep layer, histiocytic macrophages tended to gather around eosinophils. Conclusion The high numbers of CD68 (+) histiocytic macrophages mainly located in deep layer of lamina propria may be responsible for the phagocytosis of eosinophils within the polyp tissue. Therefore, it may be concluded that increased macrophages in nasal polyps do not trigger the growth of nasal polyps. Instead, they may serve to reduce the number of eosinophils in already-developed nasal polyps.


Sign in / Sign up

Export Citation Format

Share Document